Intended use:
For in vitro diagnostic use. The RIDASCREEN® VDZ Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of vedolizumab (VDZ, Entyvio®, anti- integrin α4β7) in human serum and plasma.
Product information
Vedolizumab (VDZ, Entyvio®) is approved for the treatment of patients with moderate to severe Crohn’s disease and ulcerative colitis in whom conventional therapy or anti-TNFα therapies were ineffective or not tolerated. It is a gut-specific, humanized monoclonal antibody targeting the α4β7-integrin protein, which is involved in the migration of lymphocytes to the gut. Similar as to anti-TNFα drugs, measurement of vedolizumab drug concentrations supports a personalized dosing strategy in patients treated with vedolizumab.
The RIDASCREEN® VDZ Monitoring and our other TDM assays are vital to personalize treatment of patients with Crohn’s disease and ulcerative colitis and better achieve therapeutic targets.
Key features
- CE-marked versions of the ELISA tests of KU Leuven
- Highly specific antibodies
- Ready to use reagents
- Validated for use on automated ELISA systems, e.g. the Dynex DSX®
| Art. No. | G09045 |
|---|---|
| Test format | Microtiter plate with 96 wells (12 strips with 8 removable wells each) |
| Incubation time | 1 h 40 min |
| Instructions | German English French Italian Spanish |
|---|---|
| SDS | g09045_english.zip (English) g09045_german.zip (German) g09045_french.zip (French) g09045_italian.zip (Italian) g09045_spanish.zip (Spanish) |
